title: [Efficacy of leukinferon immunocorrection in patients with maxillofacial phlegmons].
abstract: Clinical and immunological studies were carried out in patients with maxillofacial phlegmons treated by traditional methods and by traditional therapy supplemented by immunocorrection (leukinferon). Addition of leukinferon to basic therapy had a pronounced clinical and immunomodulating effect, which resulted in shorter hospitalization period and virtually complete recovery of the main immunological parameters, in contrast to traditional therapy alone. The most demonstrative parameters were the expression of the neutrophil granulocyte membrane receptors and the relationships between T-lymphocyte subpopulations, which prompted using them as the most significant diagnostic markers indicating the disease severity and treatment efficiency.
authors.forename: O V
authors.initials: OV
authors.lastname: Tsymbalov
authors.forename: N A
authors.initials: NA
authors.lastname: Nedel'ko
authors.forename: V P
authors.initials: VP
authors.lastname: Kuznetsov
authors.forename: D L
authors.initials: DL
authors.lastname: Beliaev
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D000917:Antibody Formation / Q000187:drug effects; D002481:Cellulitis / Q000188:drug therapy* / Q000276:immunology; D016207:Cytokines / Q000494:pharmacology / Q000627:therapeutic use*; D004338:Drug Combinations; D005145:Face; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007370:Interferon Type I / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D016207:Cytokines; D004338:Drug Combinations; D007370:Interferon Type I; C062252:leukinferon